09.04.2026 • News

DuPont Completes $1.8 Billion Divestiture of Aramids Business

DuPont has completed the sale of its Aramids business, including Kevlar and Nomex brands, to Arclin in a deal valued at about $1.8 billion.

Photo

DuPont recently has completed the previously-announced divestiture of its Aramids business (Kevlar and Nomex brands) to Arclin, a portfolio company of an affiliate of TJC, in a transaction valuing the business at approximately $1.8 billion.

With the closing of the transaction, DuPont receives pre-tax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in Arclin currently valued at $325 million, which is expected to represent an approximate 16% stake.

Lori Koch, DuPont Chief Executive Officer, previously commented: “The Aramids transaction further enhances the strategic focus of our portfolio, while also increasing the growth and margin profile. The transaction is structured to maximize value for our shareholders by providing significant cash proceeds at close, which will be re-deployed to further drive value creation, while also allowing DuPont shareholders to participate in Arclin’s growth potential through our retained equity interest."

The Aramids business is the inventor and largest global producer of industry-leading high-performance synthetic fibers that protect people, equipment, and structures in high-cost-of-failure applications. Aramids’ synthetic fibers, Kevlar and Nomex, are well-known brands globally with a longstanding reputation for quality, product performance and supply reliability. With about 1,900 employees and five manufacturing sites, the Aramids business generated net sales of $1.3 billion in 2024.

The results of the Aramids business were reclassified and reported as discontinued operations beginning in third quarter 2025 for current and historical periods.

Company

Logo:

DuPont Company

974 Centre Rd
19805 Wilmington, DE
US

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

most read